Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,777.20
(
-0.08%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.42
(
3.60%
)
Bitcoin
70,427.84
(
-1.14%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 99985

Wednesday, 07/28/2010 11:00:36 AM

Wednesday, July 28, 2010 11:00:36 AM

Post# of 257257

The virologic-failure rate difference was higher in ECHO trial (11.0% vs 4.4%) than in THRIVE (7.1% vs 5.3%), and there's no explanation for this either.

The disparity between the VF deltas of the two trials wasn’t statsig, as far as I know. It looks like routine statistical noise.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now